A clinical trial assessing PL 9654
Latest Information Update: 03 Jan 2022
At a glance
- Drugs PL 9654 (Primary)
- Indications Choroidal neovascularisation; Diabetic retinopathy
- Focus Adverse reactions
- Sponsors Palatin Technologies
- 03 Jan 2022 New trial record